Publication: Vitamin K antagonist control in patients with atrial fibrillation in Asia compared with other regions of the world: Real-world data from the GARFIELD-AF registry
Submitted Date
Received Date
Accepted Date
Issued Date
2016-11-15
Copyright Date
Announcement No.
Application No.
Patent No.
Valid Date
Resource Type
Edition
Resource Version
Language
File Type
No. of Pages/File Size
ISBN
ISSN
18741754
01675273
01675273
eISSN
Scopus ID
WOS ID
Pubmed ID
arXiv ID
Call No.
Other identifier(s)
2-s2.0-84982299834
Journal Title
Volume
Issue
item.page.oaire.edition
Start Page
End Page
Access Rights
Access Status
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Physical Location
Bibliographic Citation
International Journal of Cardiology. Vol.223, (2016), 543-547
Citation
Seil Oh, Shinya Goto, Gabriele Accetta, Pantep Angchaisuksiri, A. John Camm, Frank Cools, Sylvia Haas, Gloria Kayani, Yukihiro Koretsune, Toon Wei Lim, Frank Misselwitz, Martin van Eickels, Ajay K. Kakkar (2016). Vitamin K antagonist control in patients with atrial fibrillation in Asia compared with other regions of the world: Real-world data from the GARFIELD-AF registry. Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/40999.
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Vitamin K antagonist control in patients with atrial fibrillation in Asia compared with other regions of the world: Real-world data from the GARFIELD-AF registry
Alternative Title(s)
Author's Affiliation
Author's E-mail
Editor(s)
Editor's Affiliation
Corresponding Author(s)
Creator(s)
Compiler
Advisor(s)
Illustrator(s)
Applicant(s)
Inventor(s)
Issuer
Assignee
Series
Has Part
Abstract
© 2016 Elsevier Ireland Ltd Objective To compare the distribution of international normalized ratios (INRs) in patients receiving vitamin K antagonist (VKA) for newly diagnosed atrial fibrillation in Eastern and Southeastern Asia and in other regions of the world (ORW) represented in the ongoing, global observational study GARFIELD-AF. Methods and results 3621 and 13,541 patients were recruited prospectively in 2010–2013 from Asia and ORW, respectively. At baseline, excluding patients with unknown antithrombotic treatment, 1356 (37.8%) in Asia and 7081 (53.3%) in ORW received VKA (± antiplatelets). INR readings during 1-year follow-up were analyzed for VKA-treated patients with ≥ 3 measurements (878 [64.7%] patients in Asia, 4452 [62.9%] in ORW). VKA-treated patients in Asia were younger than those in ORW (mean 67.1 vs 71.3 years), with a lower CHA2DS2-VASc score (3.0 vs 3.5), but a similar HAS-BLED score (1.3 vs 1.4). Mean INR was lower in Asia than in ORW (2.0 vs 2.4). The proportion of time in the therapeutic range, defined using the multinational target of 2.0–3.0, was substantially lower in Asia (31.1% vs 54.1%). In Asia and ORW, 59.3% and 28.2% of INRs were < 2, and 9.6% and 17.7% were > 3, respectively. The same trend was found in different age groups (< 65, 65–74, ≥ 75 years). Conclusion GARFIELD-AF data demonstrate a difference in the distribution of INRs in patients from Asia versus other regions under current real-world practice. Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362.